Stock ARQULE, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News ArQule, Inc.

Equities

US04269E1073

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ArQule : Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors
AQ
Merck : KEYTRUDA Superior to Brentuximab Vedotin, a Standard of Care, in Patients with Classical Hodgkin Lymphoma in Head-to-Head Phase 3 Trial
AQ
ARQULE INC : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
ArQule, Inc. Announces Management Changes
CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P TMI Index
CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Biotechnology Select Industry Index
CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Global BMI Index
CI
Merck Sharp & Dohme Corp. completed the acquisition of ArQule, Inc..
CI
ARQULE INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
Fate Therapeutics : ArQule and Fate Therapeutics soar; Sanofi and Diplomat fall
AQ
Wall St. falls as Apple, health shares drag, tariff deadline looms
RE
Transcript : ArQule, Inc. - Special Call
ArQule : Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
BU
ArQule, Inc. Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
CI
ARQULE INC : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire ArQule, Inc. for $2.4 billion.
CI
ArQule : to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
BU
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
CI
ARQULE INC : Amendment or Waiver to Code of Ethics (form 8-K)
AQ
ArQule : to Participate in the Jefferies London Healthcare Conference on November 20, 2019
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News ArQule, Inc.